Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia. This evidence concerns the gene MDM2 and B-cell chronic lymphocytic leukemia.